Related Experiment Video
Updated: Mar 12, 2026

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Effect of Olmesartan on the Level of Oral Cancer Risk Factor PAI1
Stavros Vassiliou1, Emeka Nkenke2, Nikos Lefantzis3
1Department of Oral and Maxillofacial Surgery, National and Kapodistrian University of Athens, Medical School, Attikon Hospital, Chaidari, Athens, Greece stvasil@med.uoa.gr.
Aim:
To study if the angiotensin receptor blocker olmesartan reduces levels of plasminogen activator inhibitor 1 (PAI1), a risk factor for oral cancer, in a mouse model and therefore whether it could be used in the treatment of this malignancy.
Materials And Methods:
Twelve transgenic PAI1 mice aged 16-20 weeks were divided in two groups each containing six animals. One group was given olmesartan every day for 30 days in drinking water in an amount corresponding to their weight, 0.005 mg/g, while the second group did not receive any medication (control group). Blood samples were obtained from animals of both groups, before and after one month of olmesartan administration and plasma PAI1 levels were measured using enzyme-linked immunosorbent assay.
Results:
In the olmesartan-treated group, a significant decrease of PAI1 level was found after 1 month of treatment (11.9±8.6 vs. 21.7±7.2 ng/ml, respectively; p=0.028). However, no statistically significant difference was observed in PAI1 levels between the olmesartan-treated and control groups after one month, (p=0.177).
Conclusion:
Olmesartan did not significantly affect PAI1 levels in this mouse model.
More Related Videos
08:37Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
10:59Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Antihypertensive Drugs: Direct Renin Inhibitors
Targeted Cancer Therapies
There are several types of targeted therapies against...